256 related articles for article (PubMed ID: 35999608)
1. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.
Zhang T; Guo Z; Chen X; Dong J; Jiang H; Tang P; Wang P; Qian D; Zhang W; Pang Q
Radiat Oncol; 2022 Aug; 17(1):148. PubMed ID: 35999608
[TBL] [Abstract][Full Text] [Related]
2. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
3. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
4. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
6. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A).
Nomura M; Kato K; Ando N; Ohtsu A; Muro K; Igaki H; Abe T; Takeuchi H; Daiko H; Gotoh M; Kataoka K; Wakabayashi M; Kitagawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):480-486. PubMed ID: 28334858
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
8. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
[TBL] [Abstract][Full Text] [Related]
9. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
11. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
Ochi M; Murakami Y; Nishibuchi I; Kubo K; Imano N; Takeuchi Y; Kimura T; Hamai Y; Emi M; Okada M; Nagata Y
J Radiat Res; 2021 Jan; 62(1):142-148. PubMed ID: 33392619
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone in Esophageal Squamous Cell Carcinoma Induction chemotherapy in Esophageal Squamous Cell Carcinoma.
Hosseini Toudeshki S; Garousi M; Arefpour AM; Fadavi P; Basi A; Foroughi A; Javadinia SA
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1183-1188. PubMed ID: 38679976
[TBL] [Abstract][Full Text] [Related]
15. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
[TBL] [Abstract][Full Text] [Related]
16. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
[TBL] [Abstract][Full Text] [Related]
17. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X
Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114
[TBL] [Abstract][Full Text] [Related]
18. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy.
Gao LR; Li C; Han W; Ni W; Deng W; Tan L; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang W; Liu W; Deng L; Wang X; Zhang T; Wang J; Zhai Y; Bi N; Wang L; Hui Z; Li YX; Xiao Z
Ther Adv Med Oncol; 2022; 14():17588359221108693. PubMed ID: 35923925
[TBL] [Abstract][Full Text] [Related]
20. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
Habu T; Kumanishi R; Ogata T; Fujisawa T; Mishima S; Kotani D; Kadowaki S; Nakamura M; Hojo H; Fujiwara H; Kumagai S; Koyama S; Fujita T; Kinoshita T; Nishikawa H; Yano T; Tajika M; Muro K; Mitsunaga S; Kojima T; Bando H
Esophagus; 2023 Jul; 20(3):533-540. PubMed ID: 36750480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
